1/7/2023 0 Comments Mirc 7.41 expired bypass![]() ![]() L'invention concerne des dérivés de 3-phényl-pyrazole de formule (Ia) et des compositions pharmaceutiques correspondantes qui modulent l'activité du récepteur de sérotonine 5-HT2A. Pharmaceutical agents administered separately or together. HT2A serotonin receptor mediated disorders in combination with other The present invention also relates to the methods for the treatment of 5. Schizophrenia and related disorders, and sleep disorders, sleep disorders,ĭiabetic-related disorders, progressive multifocal leukoencephalopathy and the Psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, Symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Risk of blood clot formation, asthma or symptoms thereof, agitation or a Transient ischemic attack, angina, stroke, atrial fibrillation, reducing the Platelet aggreagation, coronary artery disease, myocardial infarction, Compounds and pharmaceuticalĬompositions thereof are directed to methods useful in the treatment of The present invention relates to certain 3-phenyl-pyrazole derivatives ofįormula (Ia) and pharmaceutical compositions thereof that modulate theĪctivity of the 5-HT2A serotonin receptor. CHOI, JIN SUN KAROLINE (United States of America).LEHMANN, JUERG (United States of America).CASPER, MARTIN (United States of America).FEICHTINGER, KONRAD (United States of America). ![]() JAYAKUMAR, HONNAPPA (United States of America).STRAH-PLEYNET, SONJA (United States of America).XIONG, YIFENG (United States of America).TEEGARDEN, BRADLEY (United States of America).(51) International Patent Classification (IPC):
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |